Related Experiment Video
Updated: May 25, 2026
Derivation of Cardiac Progenitor Cells from Embryonic Stem Cells
Published on: January 12, 2015
Human cardiomyocyte progenitor cells: a short history of nearly everything
Patrick van Vliet1, Marie-José Goumans, Pieter A Doevendans
1Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands.
Insights
Cardiomyocyte progenitor cells (CMPCs) offer a promising stem cell strategy for treating heart disease. This review summarizes current findings and future challenges for CMPC therapeutic applications.
Area of Science:
- Cardiovascular Biology
- Regenerative Medicine
- Stem Cell Therapy
Background:
- High incidence of cardiac disease necessitates novel therapeutic strategies.
- Stem cell therapy for cardiac repair is an active area of research.
- Numerous studies have explored cardiovascular progenitor cells in animal models.
Observation:
- Few cardiovascular progenitor populations identified in human hearts.
- Examples include cardiosphere-derived cells, cKit+ cells, and Isl1+ progenitors.
- The lab's focus is on cardiomyocyte progenitor cells (CMPCs).
Findings:
- This review comprehensively summarizes past findings on CMPCs.
- It highlights the current challenges in the field.
- Focuses on the therapeutic potential of CMPCs.
Implications:
- CMPCs represent a potential cell-based therapy for cardiac repair.
- Addressing current challenges is crucial for clinical translation.
- Further research may unlock the full therapeutic capacity of CMPCs.
Abstract:
The high occurrence of cardiac disease in the Western world has driven clinicians and cardiovascular biologists to look for alternative strategies to treat patients. A challenging approach is the use of stem cells to repair the heart, in itself an inspiring thought. In the past 10 years, stem cells from different sources have been under intense investigation and, as a result, a multitude of studies have been published on the identification, isolation, and characterization, of cardiovascular progenitor cells and repair in different animal models. However, relatively few cardiovascular progenitor populations have been identified in human hearts, including, but not limited to, cardiosphere-derived cells, cKit+ human cardiac stem cells , Isl1+ cardiovascular progenitors, and, in our lab, cardiomyocyte progenitor cells (CMPCs). Here, we aim to provide a comprehensive summary of the past findings and present challenges for future therapeutic potential of CMPCs.
